Senores Pharmaceuticals's receivables is $2.5B.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
The latest receivables for SENORES.NS is $2.5B as of September 2026. That compares with $22M in the prior-year period — up 11164.8% year over year. Investors often review this figure alongside Senores Pharmaceuticals's historical trend and sector peers before judging valuation or financial health.
Over the past year, SENORES.NS's receivables moved from $22M to $2.5B — a 11164.8% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Senores Pharmaceuticals's operating scale or balance-sheet position.
A receivables figure of $2.5B for SENORES.NS is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.
After noting SENORES.NS's receivables ($2.5B), review year-over-year change from $22M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.